The introduction of highly active antiretroviral therapy (HAART) has achieved a sustained improvement in the immune status of patients with AIDS. HAART has reduced infectious complications to such a degree that infections have become a relatively uncommon cause of death among people living with the human immunodeficiency virus (HIV) and, thankfully, the life expectancy of such individuals has dramatically improved.
In the pre-HAART era, AIDS-defining malignancies (Kaposi sarcoma, nonHodgkin lymphoma, and cervical cancer) afflicted HIV-positive individuals disproportionately, with incidences that were 50-200-fold higher than in the general population [1, 2] . Kaposi sarcoma, nonHodgkin lymphomas, and cervical cancer are associated with infections due to human herpesvirus 8, Epstein-Barr virus, and human papillomavirus (HPV), respectively. Their progression becomes more probable when the immune system is compromised by AIDS. Indeed, a nadir CD41 cell count is a risk factor for AIDSdefining malignancies, both in the preand post-HAART eras [2] .
The introduction of HAART reduced the incidences of Kaposi sarcoma and non-Hodgkin lymphoma by 80%-85% [1] [2] [3] , but the same cannot be said for malignancies caused by HPV. Cervical cancer incidence in HPV-positive women has not changed since the introduction of HAART; according to one study [1] , the incidence remains at approximately 150 cases per 100,000 persons-year. Other studies have shown an increasing trend, although not a statistically significant one [2, 4] . Thus, women living with HIV infection continue to be affected disproportionately by cervical cancer, with an incidence that is 10-fold higher that in the general population.
Anal squamous cell carcinoma is not formally included among the AIDSdefining malignancies, but its incidence is also greatly increased in patients living with HIV infection. We now know that .90% of anal cancers are caused by HPV infection, with most cases being caused by HPV 16 [5] . Study after study has shown a definite increasing trend in the incidence of anal cancer in the HAART era. For example, in the study by Chaturvedi et al [4] , the incidence was Many cross-sectional studies have shown that HIV positive individuals have a much higher prevalence of carcinogenic HPV infection, a much higher prevalence of infection due to multiple types, and a high prevalence of high-grade cervical or anal dysplasia. MSM-infected with HIV are also nearly all infected with 1 or more HPV types. Obviously, HAART does not have the power to clear HPV infections, and the increasing incidence of HPV-associated malignancies has been attributed to the longer survival of people with HIV infection, which provides a sufficient amount of time for the tumor progression to take place.
Although pap screening for cervical dysplasia and ablation of precancerous lesions (cervical intraepithelial neoplasia, grade 3) has been preventing cervical cancer very effectively for many decades, it remains unclear how to respond to anal cancer precursors, such as anal intraepithelial neoplasia, grades 2 and 3 (AIN 2, 3) . The article by de Pokomandy et al [6] in this issue of Clinical Infectious Diseases is a rare prospective study of a cohort of HIV-positive MSM who were followed up for 3 years and screened for HPV infection and development of AIN 2, 3. As in other reports, virtually all subjects were infected with one of the various types of mucosal HPV, and .90% were infected with more than one type [7] . Infections due to HPV 16 and 18, which have been shown to be carcinogenic HPV types associated with a higher rate of disease progression [8] , conferred greater risk for progression to AIN 2, 3. Nadir level of CD41 cell count were also significantly correlated to an increased risk of incident AIN 2, 3, as is the case for AIDS-defining malignancies. Surprisingly, or perhaps unsurprisingly, the duration of HAART did not significantly change the risk of progression to cervical intraepithelial neoplasia, grades 2 or 3. Indeed, the incidence of AIN in this cohort over a 3-year period was 39%, which was in very good agreement with the findings of a similar study in the pre-HAART era, which reported an incidence of 38% over a similar average period of follow up [9] . A second cohort study in the pre-HAART era reported an incidence of 15.2% over an average follow-up period of 20 months [10] .
These results show that HAART has not reduced the prevalence of HPV infection, has not changed the natural history of anal HPV infection in HIVpositive MSM, and has not mitigated the progression to high-grade AIN (which is likely to be a precursor to anal cancer, in much the same way that cervical dysplasia is the precursor to cervical cancer).
If anything, HAART has increased the need for monitoring anal HPV disease in individuals with HIV infection. In contrast with cervical disease, in which the detection of a cervical abnormality by regular screening is followed by effective treatment options that prevent invasive cancer, treatment of AIN is more difficult, prone to adverse effects, and plagued by a 60%-70% rate of recurrence [11] . Therefore, although a regular anal cytological screening program would seem to be reasonable, several reports have shown that this approach may be of little use without a definite cure for AIN [11, 12] . In the de Pokomandy et al [6] cohort, 39% of MSM with HIV infection developed AIN over a 3-year period, whereas only 0.12% will develop invasive cancer over the same period of time, if one extrapolates from the data presented by Bower et al [13] . Therefore, some AIN cases must not experience disease progression or may even experience disease regression. Testing for persistent infection due to HPV 16 and 18 may be a way to identify patients at increased risk of invasive cancer, but the very high prevalence of these HPV types (.40% prevalence in the de Pokomandy et al [7] cohort) will not help much in reducing the screened population.
It would be very useful in the future if cohorts like the one described in the article by de Pokomandy et al [6] could be used to study, over a longer period of time, the rate of progression of AIN to invasive cancer and, perhaps, the rate of regression, as was done with the same cohort for HPV infection [7] . Studies such as this may bring us closer to the identification of biological markers of AIN progression and provide a practical screening tool for anal HPV disease.
